Clinical Trials
3 trialsNCT04229979 2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3 Active not recruiting
NCT01757535 2025-07-08
QUAZAR AML-001
Celgene
Phase 3 Completed
NCT06180863 2023-12-26
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
Yale University
Phase 2 Withdrawn